Clinical Trial Update: Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Velcade (bortezomib) with Doxil (liposomal doxorubicin) and dexamethasone as first-line therapy for multiple myeloma; the trial has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Doxil (liposomal doxorubicin)
• Velcade (bortezomib)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED